BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 26575433)

  • 1. Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis.
    Jacobsen PL; Mahableshwarkar AR; Palo WA; Chen Y; Dragheim M; Clayton AH
    CNS Spectr; 2016 Oct; 21(5):367-378. PubMed ID: 26575433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.
    Jacobsen PL; Mahableshwarkar AR; Chen Y; Chrones L; Clayton AH
    J Sex Med; 2015 Oct; 12(10):2036-48. PubMed ID: 26331383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR; Jacobsen PL; Chen Y
    Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Summary of findings from the FDA regulatory science forum on measuring sexual dysfunction in depression trials.
    Kronstein PD; Ishida E; Khin NA; Chang E; Hung HM; Temple RJ; Yang P
    J Clin Psychiatry; 2015 Aug; 76(8):1050-9. PubMed ID: 26335083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.
    Baldwin DS; Chrones L; Florea I; Nielsen R; Nomikos GG; Palo W; Reines E
    J Psychopharmacol; 2016 Mar; 30(3):242-52. PubMed ID: 26864543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment-emergent sexual dysfunction with SSRIs and duloxetine: effectiveness and functional outcomes over a 6-month observational period.
    Dueñas H; Brnabic AJ; Lee A; Montejo AL; Prakash S; Casimiro-Querubin ML; Khaled M; Dossenbach M; Raskin J
    Int J Psychiatry Clin Pract; 2011 Nov; 15(4):242-54. PubMed ID: 22121997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of treatment-emergent sexual dysfunction and treatment effectiveness during SSRI or duloxetine therapy: 8-week data from a 6-month observational study.
    Dueñas H; Lee A; Brnabic AJ; Chung KF; Lai CH; Badr MG; Uy-Ponio T; Ruiz JR; Varrey P; Jian H; Dossenbach M
    Int J Psychiatry Clin Pract; 2011 Jun; 15(2):80-90. PubMed ID: 22121855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paroxetine, but not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults: A Randomized, Controlled Trial.
    Jacobsen P; Zhong W; Nomikos G; Clayton A
    J Sex Med; 2019 Oct; 16(10):1638-1649. PubMed ID: 31405765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder.
    Mahableshwarkar AR; Jacobsen PL; Serenko M; Chen Y; Trivedi MH
    J Clin Psychiatry; 2015 May; 76(5):583-91. PubMed ID: 26035186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder.
    Mahableshwarkar AR; Jacobsen PL; Chen Y; Simon JS
    Int J Clin Pract; 2014 Jan; 68(1):49-59. PubMed ID: 24341301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.
    Mahableshwarkar AR; Jacobsen PL; Chen Y; Serenko M; Trivedi MH
    Psychopharmacology (Berl); 2015 Jun; 232(12):2061-70. PubMed ID: 25575488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram.
    Jacobsen PL; Nomikos GG; Zhong W; Cutler AJ; Affinito J; Clayton A
    CNS Spectr; 2020 Feb; 25(1):50-63. PubMed ID: 31010445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder.
    Delgado PL; Brannan SK; Mallinckrodt CH; Tran PV; McNamara RK; Wang F; Watkin JG; Detke MJ
    J Clin Psychiatry; 2005 Jun; 66(6):686-92. PubMed ID: 15960560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder.
    Boulenger JP; Loft H; Olsen CK
    Int Clin Psychopharmacol; 2014 May; 29(3):138-49. PubMed ID: 24257717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder.
    Clayton A; Kornstein S; Prakash A; Mallinckrodt C; Wohlreich M
    J Sex Med; 2007 Jul; 4(4 Pt 1):917-29. PubMed ID: 17627739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The US Food and Drug Administration's perspective on the new antidepressant vortioxetine.
    Zhang J; Mathis MV; Sellers JW; Kordzakhia G; Jackson AJ; Dow A; Yang P; Fossom L; Zhu H; Patel H; Unger EF; Temple RJ
    J Clin Psychiatry; 2015 Jan; 76(1):8-14. PubMed ID: 25562777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vortioxetine: a New Treatment for Major Depressive Disorder.
    Connolly KR; Thase ME
    Expert Opin Pharmacother; 2016; 17(3):421-31. PubMed ID: 26679430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial.
    Inoue T; Nishimura A; Sasai K; Kitagawa T
    Psychiatry Clin Neurosci; 2018 Feb; 72(2):103-115. PubMed ID: 29160598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study.
    Findling RL; DelBello MP; Zuddas A; Emslie GJ; Ettrup A; Petersen ML; Schmidt SN; Rosen M
    J Am Acad Child Adolesc Psychiatry; 2022 Sep; 61(9):1106-1118.e2. PubMed ID: 35033635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms.
    Baldwin DS; Florea I; Jacobsen PL; Zhong W; Nomikos GG
    J Affect Disord; 2016 Dec; 206():140-150. PubMed ID: 27474960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.